Stuart Schreiber

Jnana Therapeutics, Inc. provides drug development services. The firm focuses on immunometabolism changing the metabolic pathways in immune cells to affect function; lysosomal function and mucosal defense. The company was founded by Stuart L. Schreiber, Ramnik Xavier, Joanne Kotz and Joel C. Barrish and is headquartered in Boston, MA.

Kojin Therapeutics, Inc. operates as a small-molecule therapeutics company. It focuses on translating deep biological insight into the plasticity of human cell states to develop therapeutics for cancer, fibrosis, ischemia and immune modulation. The company was founded by Benjamin Cravatt, Stephanie K. Dougan and Stuart L.Schreiber and is headquartered in the United States.

Magnet Biomedicine, Inc. is a biotechnology company based in Cambridge, MA. Magnet Biomedicine is advancing molecular glue discovery with rational selection and design through their TrueGlue discovery platform. The company applies cutting-edge advancements in human biology and proteomics to identify fit-for-purpose glues that maximize therapeutic impact and offer prominent benefits such as improving selectivity, inducing biological synergy on defined targets, and addressing historically undruggable proteins. Magnet Biomedicine is revolutionizing human medicine with molecular glues and is tackling multiple disease areas and biological mechanisms, including cancer, cardiovascular disease, and immune disorders. The company was founded by Benjamin F. Cravatt, Stuart L. Schreiber, Michael Rosbash, Richa Saxena.

Kisbee Therapeutics, Inc develops novel therapeutic agents for neurodegenerative diseases. The company was founded by Benjamin Cravatt, Jennifer Lippincott Schwartz, Emily Ricqu and Stuart L.Schreiber and is headquartered in DE.

Belharra Therapeutics, Inc. is a drug discovery company that utilizes a unique photoaffinity-based chemoproteomics platform to identify novel small molecule drug candidates for previously difficult-to-treat diseases and conditions. The company is based in San Diego, CA, with its primary lab and offices located in the area. Belharra's proprietary discovery engine allows for the identification of small molecule starting points for drug development on any protein, in any conformational state, and in any cell type. The company was founded in 2021 by John Teijaro, Christopher G. Parker, Stuart L. Schreiber, and Benjamin F. Cravatt, and has since been led by CEO Jeffrey Jonker.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.